Statin medications lower cholesterol levels and have an anti-inflammatory effect. They should be used in combination with lifestyle changes to reduce heart disease risk.
Studies of people with heart disease have shown that lowering cholesterol levels can reduce the risk of dying from heart disease, having a heart attack, and/or needing heart bypass surgery.
Even among people who do not have heart disease, lowering cholesterol levels can reduce the risk of developing heart disease and related deaths.
"Statins have other effects in addition to their effects on cholesterol levels," says Mark Abramowicz, MD, editor of The Medical Letter on Drugs and Therapeutics, a non-profit newsletter that critically appraises drugs. "They have an anti-inflammatory effect, and they improve the ability of blood vessels to widen. However, they should not be used as a substitute for lifestyle changes."
Currently, three statins are available as generics, however, statins differ in potency. The two most potent medications, Crestor (rosuvastatin) and Lipitor (atorvastatin), currently are not available as generics.
"When choosing a statin, a major consideration should be the magnitude of LDL-C reduction required," says Dr. Abramowicz. "If moderate lowering is needed, lovastatin, simvastatin or a low dose of atorvastatin (10 mg) would be a reasonable choice. Intense LDL-C reduction can be obtained by using atorvastatin or rosuvastatin, but clinical outcomes data are lacking for rosuvastatin. In patients with acute coronary syndromes, atorvastatin is preferred."
When statins alone do not control lipid levels, they may be combined with a number of other medications, including bile acid sequestrants, Zetia (ezetimibe), fibrates, niacin and fish oil capsules. Welchol (colesevelam) is tolerated much better than resin bile acid sequestrants and is less likely to interfere with intestinal absorption of other drugs.
For patients with low levels of high density cholesterol (HDL-C), high triglycerides and a normal LDL-C, statins combined with fenofibrate, niacin or fish oil are recommended.
"When both HDL-C and LDL-C are low in patients at risk for coronary disease, a fibrate alone, niacin alone, or a combination of niacin with a statin would be a reasonable choice," says Dr. Abramowicz. "Two fibrate preparations are available in the United States, and clinical benefit is best documented for gemfibrozil, which is available as a generic."
When taken by patients who don't have coronary disease, but do have risk factors such as high LDL-C, low HDL-C, hypertension or diabetes, pravastatin, lovastatin and Lipitor (atorvastatin) have been shown to reduce the risk of subsequent cardiovascular problems. In patients with existing heart disease, treatment with various statins lowered the incidence of heart attack and stroke, and decreased mortality from all causes, even in patients with normal LDL-C levels. Statin therapy for patients undergoing elective angioplasty reduced the rate of subsequent heart attacks by 43%, from 5.2% to 3%.
PREVENTIVE SERVICES
Health Net is rolling out a Medicare Advantage Special Needs Plan (SNP) designed for seniors with high cholesterol. While most SNPs focus on managing chronic diseases, the Sage plan focuses on prevention.
The benefits are almost identical to the plan's Medicare Advantage product, says Richard Jacobs, MD, chief medical officer and vice president of medical operations for Health Net of Arizona. "Sage is an engagement strategy. It means we don't have to waste time and resources searching for the people who have this problem. Since everyone in the plan has hypercholesterolemia, we can focus resources and attention on them."
Muthiah “Muthu” Vaduganathan Discusses the Role of SGLT2 Inhibitors in Heart Failure Treatment
March 27th 2024Editors of Managed Healthcare Executive spoke with Muthiah “Muthu” Vaduganathan MD, MPH, consultant cardiologist at Brigham and Women's Hospital and a member of faculty at Harvard Medical School, about the evolving treatment landscape for heart failure, emphasizing the use of SGLT2 inhibitors alongside other foundational therapies.
Read More
In this second part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein spoke with CeCi Connolly and Margaret "Meg" Murray about Medicare Advantage utilization and challenges, highlighting proposed CMS payment cuts and prior authorization issues.
Listen
With aging populations, osteoporosis rates are set to increase, and researchers are looking for the next innovative drug to help prevent or manage the bone disease as there is currently no drug that completely does so effectively, according to a recent study published in Advanced Science.
Read More
In this first part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein kicks off our new podcast series "DC Roundtable," with guests Margaret "Meg" Murray, CEO of the Association of Community Affiliated Plans, and member of MHE's Editorial Advisory Board, and CeCi Connolly, president and CEO of the Alliance of Community Health Plans, for a discussion on healthcare policy issues.
Listen
2024 Emerging Leaders in Healthcare — Submit For a Chance to Be Featured in MHE's August Issue
March 26th 2024MHE Editors are seeking diverse healthcare professionals from different backgrounds and healthcare sectors, with individual interests. Eligible candidates are early or mid-career leaders with less than 10 years of experience. Award winners will enjoy complimentary passes to the PBMI Annual National Meeting in Orlando, Florida, from Sept. 4-6. Additional perks include a feature in our August issue, a subscription to MHE and more!
Read More